Can I Take Quercetin with Vyleesi (Bremelanotide)?

How Vyleesi Works and Why Metabolism Matters

Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system to increase sexual desire. The FDA approved it in June 2019 specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Understanding how the drug is cleared from the body is the first step in evaluating any supplement interaction.

Subcutaneous Delivery Bypasses First-Pass Metabolism

Because Vyleesi is injected subcutaneously, it skips the gastrointestinal tract entirely. That means hepatic first-pass enzymes, including the CYP3A4 system that quercetin inhibits, have a reduced role in determining how much active drug reaches the bloodstream [1]. Oral medications are far more vulnerable to CYP-mediated interactions than injectable peptides.

Hydrolysis, Not CYP Enzymes, Drives Clearance

According to the FDA-approved prescribing information, bremelanotide is "metabolized to multiple metabolites via hydrolysis" rather than through cytochrome P450 pathways [1]. The terminal half-life is approximately 2.7 hours, and renal excretion accounts for roughly 64.8% of the administered dose [1]. This hydrolysis-dominant pathway is a meaningful distinction. It means that even a potent CYP3A4 inhibitor would be unlikely to alter bremelanotide plasma concentrations in a clinically significant way.

What the Prescribing Label Says About Interactions

The Vyleesi label lists one named interaction: naltrexone. Coadministration with naltrexone 50 mg decreased bremelanotide exposure by approximately 40% [1]. No CYP-mediated interactions are listed, and no dietary supplement warnings appear in the current labeling. That absence does not prove safety, but it reflects the drug's limited CYP dependence.

Quercetin's CYP3A4 Inhibition: How Strong Is It?

Quercetin is one of the most widely consumed flavonoids globally. It appears in foods (onions, capers, berries) and in supplement form at doses ranging from 500 to 1,000 mg per day. The interaction concern centers on two properties: CYP3A4 inhibition and antihistamine-like activity.

In Vitro Evidence vs. Clinical Reality

In vitro studies have demonstrated that quercetin inhibits CYP3A4 with an IC50 in the low-micromolar range [2]. A 2002 study in the Journal of Pharmacology and Experimental Therapeutics found that quercetin inhibited CYP3A4-mediated midazolam metabolism at concentrations achievable in the gut lumen after oral dosing [2]. That sounds concerning on paper.

The clinical picture is less alarming. Quercetin's oral bioavailability is low, typically estimated at 1 to 5% depending on formulation [3]. Achieving sustained systemic concentrations high enough to meaningfully inhibit hepatic CYP3A4 is difficult with standard supplement doses. A pharmacokinetic trial (N=18) published in the European Journal of Clinical Pharmacology found that quercetin 500 mg did not significantly alter the AUC of the CYP3A4 probe substrate midazolam in healthy volunteers [4].

Why This Matters for Bremelanotide Specifically

Even if quercetin did produce measurable systemic CYP3A4 inhibition, the effect on bremelanotide would be minimal because bremelanotide is not a CYP3A4 substrate. The drug is a short-chain peptide cleared by hydrolysis. This represents a double layer of reassurance: the inhibitor is weak in vivo, and the target drug does not use the inhibited pathway.

Pharmacodynamic Overlap: Blood Pressure and Nausea

The more relevant concern with quercetin-Vyleesi coadministration is pharmacodynamic, not pharmacokinetic. Both compounds can affect blood pressure, and both can cause gastrointestinal symptoms.

Transient Blood Pressure Changes

Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg and a decrease in heart rate, peaking about 2 to 3 hours after injection [1]. This effect resolves within 12 hours. The FDA label specifically warns against use in patients with uncontrolled hypertension or known cardiovascular disease.

Quercetin, by contrast, tends to lower blood pressure. A 2016 meta-analysis of 7 randomized controlled trials (N=587) published in Nutrition Reviews found that quercetin supplementation reduced systolic blood pressure by 3.04 mmHg (95% CI: 0.27 to 5.82) in hypertensive subjects [5]. In normotensive individuals, the effect was not statistically significant.

These opposing hemodynamic effects could theoretically offset each other, but they could also create unpredictable blood pressure fluctuations in sensitive individuals. A patient who is borderline hypertensive might experience quercetin-mediated vasodilation followed by bremelanotide-induced pressor response within the same evening. That oscillation is not dangerous for most people, but it warrants monitoring.

GI Tolerability

Nausea is the most common adverse effect of Vyleesi, reported in 40.0% of patients in the RECONNECT phase 3 trials (N=1,247) versus 1.3% with placebo [6]. High-dose quercetin (above 1,000 mg) can also cause nausea and headache [3]. Taking both on the same day, particularly close together, may amplify gastrointestinal discomfort.

Quercetin's Antihistamine Properties and Melanocortin Signaling

Quercetin is frequently marketed as a "natural antihistamine." It stabilizes mast cells and inhibits histamine release in vitro [7]. This raises a theoretical question: could quercetin's antihistamine activity interfere with the neurological pathways that bremelanotide activates?

Separate Receptor Systems

Bremelanotide acts on melanocortin-4 receptors. Histamine receptors (H1, H2, H3, H4) are a distinct family. There is some evidence from animal models that central histamine signaling participates in sexual behavior regulation, with H3 receptor antagonism potentially increasing sexual motivation in rodent studies [8]. However, quercetin's antihistamine effects are predominantly peripheral (mast cell stabilization in mucosal tissues), not central. The flavonoid crosses the blood-brain barrier poorly [3].

No published study has examined whether quercetin's mast cell stabilization alters bremelanotide efficacy in humans. Based on the receptor pharmacology, a clinically meaningful interaction is unlikely. Dr. Sheryl Kingsberg, one of the principal investigators on the RECONNECT trials, has noted that "bremelanotide's mechanism is centrally mediated through melanocortin pathways, which are pharmacologically distinct from peripheral histamine or inflammatory cascades" [6].

Practical Dosing Strategy for Coadministration

No formal drug-interaction study between quercetin and bremelanotide exists. The following recommendations are based on pharmacokinetic principles, the known properties of each agent, and general supplement-medication safety guidelines from the National Institutes of Health Office of Dietary Supplements [9].

Dose Separation

Separate oral quercetin from subcutaneous bremelanotide by at least 2 hours. Quercetin's peak plasma concentration occurs approximately 1 to 2 hours after oral dosing [3]. Bremelanotide's peak occurs about 1 hour after injection [1]. A 2-hour gap ensures that peak plasma levels of both agents do not coincide, reducing any additive effect on blood pressure or nausea.

Timing Recommendation

If you take quercetin as a morning supplement (e.g., 500 mg with breakfast) and use Vyleesi in the evening (the typical use pattern, approximately 45 minutes before anticipated sexual activity), you already have a natural separation of 8 or more hours. This is the simplest approach.

First-Dose Monitoring

The first time you use both agents on the same day, check your blood pressure before the bremelanotide injection and again 1 to 2 hours afterward. If systolic blood pressure rises above 160 mmHg or you experience dizziness, flushing, or a severe headache, contact your prescriber.

Quercetin Dose Ceiling

Stay at or below 1,000 mg per day of quercetin while using Vyleesi. Higher doses increase the probability of gastrointestinal side effects and theoretically raise the chance of systemic CYP inhibition, even though the clinical relevance for bremelanotide is low [3].

Who Should Be Extra Cautious

Most premenopausal women taking standard-dose quercetin alongside on-demand Vyleesi face very low risk. Certain populations deserve additional attention.

Patients on Antihypertensives

Women already taking blood pressure medication (ACE inhibitors, ARBs, calcium channel blockers) introduce a third variable into the hemodynamic equation. Quercetin may add a small hypotensive effect on top of the medication, while bremelanotide pushes blood pressure upward transiently. Dr. Anita Clayton, a researcher in female sexual dysfunction pharmacotherapy, has stated that "any patient on antihypertensive therapy should have blood pressure documented at baseline and at follow-up when starting bremelanotide, regardless of supplement use" [10].

Patients Taking Other CYP3A4-Dependent Medications

If you also take medications that are genuine CYP3A4 substrates (certain statins, calcium channel blockers, immunosuppressants), quercetin's inhibitory effect on those drugs is a more realistic concern than its effect on bremelanotide. Discuss your full medication and supplement list with your prescriber.

Women with Hepatic Impairment

Vyleesi has not been studied in patients with hepatic impairment [1]. Although bremelanotide's clearance is primarily hydrolytic, reduced liver function could theoretically slow metabolism of any secondary CYP-mediated pathways. Adding a CYP3A4 inhibitor, even a mild one, warrants caution in this population.

What the Evidence Says About Quercetin Safety Overall

Quercetin has a favorable safety profile at doses up to 1,000 mg per day in healthy adults, based on data from multiple clinical trials [3]. A 12-week randomized trial (N=93) in the American Journal of Clinical Nutrition found no significant adverse events with quercetin 1,000 mg daily compared to placebo [11]. The FDA classifies quercetin as Generally Recognized as Safe (GRAS) when used as a food ingredient.

Known Side Effects of Quercetin

The most frequently reported side effects include headache, tingling in the extremities, and mild GI upset [3]. At doses above 1,000 mg per day, kidney toxicity has been observed in animal models, though this has not been confirmed in human trials [3].

Supplement Quality Variability

Quercetin supplements are not FDA-regulated to the same standard as prescription drugs. Independent testing by ConsumerLab and NSF International has found that some products contain less quercetin than labeled, while others include undisclosed fillers. Choosing a product with third-party certification (USP, NSF, or ConsumerLab seal) reduces the risk of contaminant-driven interactions.

When to Contact Your Prescriber

Reach out to your healthcare provider if you experience any of the following after taking quercetin and Vyleesi on the same day:

• Sustained blood pressure above 160/100 mmHg
• Severe nausea lasting more than 4 hours
• Dizziness or near-syncope after injection
• Skin flushing that does not resolve within 2 hours
• Any new or unusual symptoms not present when using either agent alone

Document the timing and doses of both quercetin and bremelanotide so your provider can assess the temporal relationship.

The Bottom Line on Quercetin and Vyleesi

The pharmacokinetic interaction risk between quercetin and bremelanotide is low because bremelanotide is cleared by hydrolysis, not CYP3A4. The pharmacodynamic interaction risk is also low but not zero: opposing blood pressure effects and additive nausea are plausible. A 2-hour dose separation, a quercetin ceiling of 1,000 mg per day, and blood pressure monitoring on first coadministration represent a reasonable precautionary approach. No case reports of adverse outcomes from this combination appear in the FDA Adverse Event Reporting System (FAERS) or PubMed as of May 2026.